HC Wainwright Has Positive Forecast for UNCY FY2024 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Stock analysts at HC Wainwright increased their FY2024 earnings per share estimates for shares of Unicycive Therapeutics in a report released on Thursday, November 14th. HC Wainwright analyst E. Arce now anticipates that the company will earn ($0.11) per share for the year, up from their previous forecast of ($0.12). HC Wainwright has a “Buy” rating and a $2.50 price objective on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ FY2025 earnings at ($0.34) EPS, FY2026 earnings at ($0.22) EPS, FY2027 earnings at $0.02 EPS and FY2028 earnings at $0.53 EPS.

Separately, Benchmark reiterated a “speculative buy” rating and issued a $3.00 target price on shares of Unicycive Therapeutics in a research note on Friday, September 6th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $5.13.

Unicycive Therapeutics Stock Performance

Shares of NASDAQ UNCY opened at $0.49 on Monday. The business has a 50 day simple moving average of $0.43 and a 200 day simple moving average of $0.54. Unicycive Therapeutics has a 52 week low of $0.20 and a 52 week high of $1.82. The stock has a market cap of $50.34 million, a price-to-earnings ratio of -0.50 and a beta of 2.29.

Institutional Trading of Unicycive Therapeutics

Several large investors have recently made changes to their positions in UNCY. Great Point Partners LLC acquired a new stake in Unicycive Therapeutics in the 3rd quarter worth approximately $3,491,000. Walleye Capital LLC bought a new position in shares of Unicycive Therapeutics in the third quarter valued at approximately $2,040,000. BVF Inc. IL lifted its stake in shares of Unicycive Therapeutics by 70.5% in the first quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock worth $4,984,000 after buying an additional 1,493,462 shares during the last quarter. Acuta Capital Partners LLC bought a new stake in shares of Unicycive Therapeutics during the 3rd quarter worth $807,000. Finally, Bleakley Financial Group LLC acquired a new position in Unicycive Therapeutics in the 3rd quarter valued at $33,000. Institutional investors own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.